Its oncology platform uses the systemic, non-viral Oncoprex® Delivery System, which encapsulates gene-expressing plasmids in lipid-based nanoparticles in a lipoplex form, administered intravenously to restore expression of tumor suppressor proteins in cancer cells. Each of Genprex's lung cancer clinical programs with Reqorsa has received FDA Fast Track Designation, and the SCLC program has received FDA Orphan Drug Designation.
Cyborg Score Rationale
The company reported a net income of -$3.8 million in Q3 2025, and analysts highlighted concerns regarding the company's cash burn situation in January 2026, with financial health assessed as weak with a Piotroski F-Score of 2 out of 9 in February 2026. As of Q3 2025, the company reported only $1.10 million in cash and cash equivalents against a significant cash burn of over $11.21 million in operating activities for the nine months ended September 30, 2025, with cash position projected to be sufficient only into March 2026.
Top Insights
Lead candidate Reqorsa® Gene Therapy is advancing in lung cancer trials, bolstered by a new U.S. patent granted in November 2025 that extends protection through 2037.
Market capitalization of just over $5.04 million as of November 2025 reflects the high-risk nature of a clinical-stage company whose value is tied entirely to future clinical success.
Institutional ownership is low at 0.73%, while insider ownership is high at 59.12%, suggesting significant insider confidence.
Key action is to track the interim analysis data from the Acclaim-3 trial, expected after the 25th patient reaches 18 weeks of follow-up, as this will be the next major catalyst.
Named Competitors
Gene Therapies — Leading gene therapy company with approved products
Cell & Gene Therapy — Clinical-stage cell and gene therapy company
mRNA-based Therapeutics — RNA technology platform for multiple disease areas
Recent Developments
(November 2025) New U.S. patent granted for Reqorsa extending protection through 2037
(November 2025) Phase 1 study in NSCLC combining Reqorsa with Tagrisso launched
(October 2025) Registered direct offerings totaling approximately $18.1 million secured
Open the full interactive Genprex, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.